COMPANY

Avidity Biosciences

HQ: San Diego, CA source · aviditybiosciences.com ↗ · West Coast

Status: Acquired, now part of Novartis · How status works

New owner: Acquired by Novartis (closed on or before 2026-02-27) · source (Feb 27, 2026) · Ownership changes

Keywords: antibody Atrophic Muscular Disorders Musculoskeletal Diseases Nervous System Diseases Muscular Dystrophies Duchenne Muscular Dystrophy DM1 Myotonic Dystrophy 1 Myotonic Dystrophy Myotonic Disorders Steinert Disease Facioscapulohumeral Muscular Dystrophy FSHD1 FSHD2 Fascioscapulohumeral Muscular Dystrophy Fascioscapulohumeral Muscular Dystrophy Type 1 Fascioscapulohumeral Muscular Dystrophy Type 2 Facioscapulohumeral Muscular Dystrophy 1 Facio-Scapulo-Humeral Dystrophy Facioscapulohumeral Muscular Dystrophy 2 FSH Muscular Dystrophy Landouzy Dejerine Dystrophy Landouzy-Dejerine Muscular Dystrophy Landouzy-Dejerine Syndrome Facioscapulohumeral Atrophy Muscular Diseases Neuromuscular Diseases Inborn Genetic Diseases DMD Myotonic Dystrophy Type 1 (DM1) Dystrophy Myotonic Myotonic Muscular Dystrophy Myotonia Exon 44 FMD2 Facioscapulohumeral Muscular Dystrophies Facioscapulohumeral Atrophies Landouzy-Dejerine Dystrophies Progressive Muscular Dystrophy

Profile checked Oct 10, 2026

11Trials (company is sponsor)

Timeline

Sep 1, 2026 Trial start 3: A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping source ↗
Jun 26, 2025 Trial start Phase 3: Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 source ↗
Jun 10, 2025 Trial start Phase 3: A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD source ↗
Jul 25, 2024 Trial start 2: Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) source ↗
May 30, 2024 Trial start Phase 3: Global Study of Del-desiran for the Treatment of DM1 source ↗
Jan 22, 2024 Trial start Phase 2: Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping source ↗
Apr 4, 2023 Trial start 1: Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) source ↗
Nov 9, 2022 Trial start Phase 1/Phase 2: Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping source ↗
Aug 4, 2022 Trial start Phase 2: Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients source ↗
Oct 28, 2021 Trial start Phase 1/Phase 2: Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients source ↗

Upcoming milestones

Apr 30, 2027 (ESTIMATED) · Phase 2 · Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping · NCT06244082
2028-05 (ESTIMATED) · Phase 3 · A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD · NCT07038200
2029-05 (ESTIMATED) · 3 · A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping · NCT07587242
2030-04 (ESTIMATED) · 2 · Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) · NCT06547216
2030-10 (ESTIMATED) · Phase 3 · Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 · NCT07008469

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT07250737	Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping	Not listed	Available	Not listed	Not listed
NCT07587242	A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping	3	Recruiting	Sep 1, 2026	2029-05 (estimated)
NCT05027269	Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients	Phase 1/Phase 2	Completed	Oct 28, 2021	Feb 14, 2023 (actual)
NCT05479981	Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients	Phase 2	Completed	Aug 4, 2022	Sep 5, 2025 (actual)
NCT06411288	Global Study of Del-desiran for the Treatment of DM1	Phase 3	Completed	May 30, 2024	Jul 23, 2026 (actual)
NCT07008469	Global Open-Label Extension Study of Del-desiran for the Treatment of DM1	Phase 3	Enrolling by invitation	Jun 26, 2025	2030-10 (estimated)
NCT06244082	Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping	Phase 2	Active, not recruiting	Jan 22, 2024	Apr 30, 2027 (estimated)
NCT07038200	A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD	Phase 3	Recruiting	Jun 10, 2025	2028-05 (estimated)
NCT05747924	Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)	1	Completed	Apr 4, 2023	Mar 18, 2026 (actual)
NCT06547216	Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)	2	Active, not recruiting	Jul 25, 2024	2030-04 (estimated)
NCT05670730	Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping	Phase 1/Phase 2	Completed	Nov 9, 2022	Nov 25, 2024 (actual)